Lung Disease-Focused Insmed 'Must-Own' Name For Investors
1. William Blair initiated coverage on Insmed, highlighting strong growth potential. 2. Brinsupri is the first FDA-approved treatment for non-cystic fibrosis bronchiectasis. 3. Analyst predicts peak sales could reach $15 billion by 2035. 4. Insmed stock has risen over 450% since positive Phase III results. 5. Strong launch of Brinsupri may enhance Insmed's market valuation significantly.